GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More Details
Adequate balance sheet with concerning outlook.
Share Price & News
How has GeNeuro's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GNRO is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: GNRO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: GNRO exceeded the French Biotechs industry which returned 35.2% over the past year.
Return vs Market: GNRO underperformed the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is GeNeuro's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StBreakeven On The Horizon For GeNeuro SA (EPA:GNRO)
5 months ago | Simply Wall StAnalysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long
7 months ago | Simply Wall StOur View On GeNeuro's (EPA:GNRO) CEO Pay
Is GeNeuro undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GNRO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GNRO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GNRO is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: GNRO is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GNRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GNRO is overvalued based on its PB Ratio (9.8x) compared to the FR Biotechs industry average (4.3x).
How is GeNeuro forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GNRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GNRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if GNRO's revenue is forecast to grow faster than the French market.
High Growth Revenue: Insufficient data to determine if GNRO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GNRO's Return on Equity is forecast to be very high in 3 years time (119.6%).
How has GeNeuro performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNRO is currently unprofitable.
Growing Profit Margin: GNRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GNRO is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare GNRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: GNRO has a negative Return on Equity (-107.9%), as it is currently unprofitable.
How is GeNeuro's financial position?
Financial Position Analysis
Short Term Liabilities: GNRO's short term assets (€11.2M) exceed its short term liabilities (€2.2M).
Long Term Liabilities: GNRO's short term assets (€11.2M) exceed its long term liabilities (€2.6M).
Debt to Equity History and Analysis
Debt Level: GNRO's debt to equity ratio (2.2%) is considered satisfactory.
Reducing Debt: GNRO's debt to equity ratio has reduced from 10.4% to 2.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if GNRO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GNRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is GeNeuro current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GNRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GNRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GNRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GNRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GNRO's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jesus Martin-Garcia (58 yo)
Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...
CEO Compensation Analysis
Compensation vs Market: Jesus's total compensation ($USD892.10K) is above average for companies of similar size in the French market ($USD297.33K).
Compensation vs Earnings: Jesus's compensation has increased whilst the company is unprofitable.
Experienced Management: GNRO's management team is considered experienced (3.2 years average tenure).
Experienced Board: GNRO's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GeNeuro SA's company bio, employee growth, exchange listings and data sources
- Name: GeNeuro SA
- Ticker: GNRO
- Exchange: ENXTPA
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €86.000m
- Shares outstanding: 20.48m
- Website: https://www.geneuro.ch
Number of Employees
- GeNeuro SA
- 3 chemin du Pré-Fleuri
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal an...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 18:41|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.